InhaleRx Limited

As of December 31, 2025, InhaleRx Limited has 239.36M shares outstanding.

These figures are as of December 31, 2025.

These figures are as of December 31, 2025. InhaleRx Limited trades at an EV/FCF ratio of 40.15, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2025, InhaleRx Limited maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.09, indicating conservative leverage, while an interest coverage ratio of -18.13 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -168.58, reflecting losses generated across the asset base.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -21.83, meaning InhaleRx Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

InhaleRx Limited's most recent stock split took place on December 9, 2020 with a 100:103 split ratio.

As of December 31, 2025, InhaleRx Limited has an Altman Z-Score of -24.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.